查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790450

美国抗真菌药物市场规模、份额和趋势分析报告：按药物类别、适应症、剂型、分销管道和细分市场预测，2025-2030 年

U.S. Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), By Indication, By Dosage Form, By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国抗真菌药物市场摘要

美国抗真菌药物市场规模预计在 2024 年为 60.5 亿美元，预计在 2030 年将达到 72 亿美元，2025 年至 2030 年的复合年增长率为 3.0%。真菌感染疾病的日益普及正在推动市场扩张。

真菌感染疾病的种类繁多，从足癣、癣和阴道酵母菌感染疾病到严重的全身性疾病，如念珠菌血症、曲菌症和毛霉菌病。疾病预防控制中心将耳Auris和抗药性曲菌种视为严重威胁，需要改进治疗方法方法并加强感染控制。美国抗真菌药物产业受到真菌感染疾病持续增加的推动，主要发生在癌症患者、移植患者和爱滋病毒感染者等免疫免疫力缺乏的人群中，以及ICU入院人数的增加和导管和人工呼吸器等医疗设备使用增加。这些族群特别容易受到灰指甲和曲菌症等性行为感染，需要全身性抗真菌治疗。此外，甲癣和皮肤丝状菌症病等浅层真菌病仍然普遍存在且经常復发，对口服和外用抗真菌药物的需求保持稳定。监测数据表明，非白色念珠菌引起大约三分之二的血流感染疾病，其中 6% 的分离株对Fluconazole有抗药性，2% 对Echinocandins有抗药性。

根据美国疾病管制与预防中心 (CDC) 2024 年 5 月的数据，每年有超过 7.5 万例住院病例和近 900 万人次门诊就诊，均与真菌感染有关。 2024 年 4 月的数据显示，每年约有 2.5 万例念珠菌症病病例，约三分之一的患者在住院期间死亡。公共卫生工作正在稳步提高人们对真菌感染的认识。 CDC 的「真菌疾病宣传週」定于 2025 年 9 月举行，旨在促进早期诊断并加强抗药性监测。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国抗真菌药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国抗真菌药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 美国抗真菌药物市场：产品线分析

第四章美国抗真菌药物市场：药物类别估计与趋势分析

  • 药品类别细分仪表板
  • 美国抗真菌药物市场：药物类别变化分析
  • 美国抗真菌药物市场规模及趋势分析（依药物类别，2018-2030年）
  • Azole
  • Echinocandins
  • Polyenes
  • Allylamines
  • 其他的

第五章：美国抗真菌药物市场：适应症估计与趋势分析

  • 指示细分仪表板
  • 美国抗真菌药物市场：适应症变化分析
  • 美国抗真菌药物市场规模及趋势分析（按适应症，2018-2030）
  • 皮肤丝状菌症
  • 曲菌症
  • 念珠菌症
  • 其他的

第六章：美国抗真菌药物市场：剂型估计与趋势分析

  • 剂型细分细分仪表板
  • 美国抗真菌药物市场：剂型变化分析
  • 美国抗真菌药物市场规模及趋势分析（按剂型，2018-2030）
  • 口服药物
  • 软膏
  • 粉末
  • 其他的

第七章：美国抗真菌药物市场：通路评估与趋势分析

  • 分销通路细分仪表板
  • 美国抗真菌药物分销管道：渠道波动分析
  • 美国抗真菌药物市场规模及趋势分析（按分销管道，2018-2030）
  • 医院药房
  • 零售药局
  • 其他的

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • Novartis Pharmaceuticals Corporation
    • Pfizer Inc.
    • Bayer AG
    • Sanofi.
    • Merck &Co., Inc.
    • GSK plc.
    • Abbott.
    • GLENMARK PHARMACEUTICALS INC., USA
    • Enzon Pharmaceuticals, Inc.
    • Astellas Pharma US, Inc.
Product Code: GVR-4-68040-668-1

U.S. Antifungal Drugs Market Summary

The U.S. antifungal drugs market was estimated at USD 6.05 billion in 2024 and is projected to reach USD 7.20 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing incidence of fungal infections drives market expansion.

Fungal infections cover a broad range of conditions, from athlete's foot, ringworm, and vaginal yeast infections to severe systemic diseases such as candidemia, aspergillosis, and mucormycosis. The CDC identifies Candida auris and resistant Aspergillus species as serious threats, necessitating therapeutic advances and enhanced infection control. The U.S. antifungal drugs industry is mainly driven by a consistent increase in fungal infections among immunocompromised groups, such as cancer patients, transplant recipients, and individuals with HIV; a rise in ICU admissions; and the increased use of medical devices such as catheters and ventilators. This population is particularly vulnerable to invasive infections such as candidemia and aspergillosis, which require systemic antifungal treatments. Furthermore, superficial fungal infections such as onychomycosis and dermatophytosis remain widespread and frequently recur, maintaining steady demand for oral and topical antifungal medications. Surveillance data show that non-albicans Candida species cause approximately two-thirds of bloodstream infections, with 6% of isolates resistant to fluconazole and 2% of C. glabrata isolates resistant to echinocandins, highlighting the need for newer and more effective antifungal therapies.

Systemic fungal infections continue to pose a significant healthcare challenge in the U.S. Each year, more than 75,000 hospitalizations and nearly 9 million outpatient visits are attributed to fungal diseases, as per the CDC in May 2024. As per April 2024 data, ab out 25,000 cases of candidemia occur annually, with roughly one-third of patients dying during their hospital stay. Public health initiatives are steadily raising awareness of fungal diseases. The CDC's Fungal Disease Awareness Week, scheduled for September 2025, aims to promote early diagnosis and enhance resistance surveillance.

U.S. Antifungal Drugs Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. antifungal drugs market on the basis of drug class, indication, dosage form, and distribution channel:

  • Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others
  • Indication Outlook (Revenue, USD Billion, 2018 - 2030)
  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Others
  • Dosage Form Outlook (Revenue, USD Billion, 2018 - 2030)
  • Oral Drugs
  • Ointments
  • Powders
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
  • Hospital Pharmacies
  • Retails Pharmacies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug class
    • 1.2.2. Indication
    • 1.2.3. Dosage form
    • 1.2.4. Distribution channel
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Indication outlook
    • 2.2.3. Dosage form
    • 2.2.4. Distribution channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Antifungal Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Antifungal Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Antifungal Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antifungal Drugs Market: Drug class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. U.S. Antifungal Drugs Market: Drug Class Movement Analysis
  • 4.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Azoles
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Echinocandins
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Polyenes
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Allylamines
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Antifungal Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Segment Dashboard
  • 5.2. U.S. Antifungal Drugs Market: Indication Movement Analysis
  • 5.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
  • 5.4. Dermatophytosis
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Aspergillosis
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Candidiasis
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis

  • 6.1. Dosage Form Segment Dashboard
  • 6.2. U.S. Antifungal Drugs Market: Dosage Form Movement Analysis
  • 6.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Dosage Form, 2018 to 2030 (USD Billion)
  • 6.4. Oral Drugs
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Ointments
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Powders
    • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Segment Dashboard
  • 7.2. U.S. Antifungal Distribution Channel: Indication Movement Analysis
  • 7.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5. Retails Pharmacies
    • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Novartis Pharmaceuticals Corporation
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bayer AG
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Sanofi.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Merck & Co., Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. GSK plc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Abbott.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. GLENMARK PHARMACEUTICALS INC., USA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Enzon Pharmaceuticals, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Astellas Pharma US, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 U.S. antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 4 U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 5 U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Financial performance
  • Table 7 Key companies undergoing expansions
  • Table 8 Key companies undergoing acquisitions
  • Table 9 Key companies undergoing collaborations
  • Table 10 Key companies launching new products/services
  • Table 11 Key companies undergoing partnerships
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antifungal drugs market: market outlook
  • Fig. 10 U.S. antifungal drugs market competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antifungal drugs market driver impact
  • Fig. 16 U.S. antifungal drugs market restraint impact
  • Fig. 17 U.S. antifungal drugs market strategic initiatives analysis
  • Fig. 18 U.S. antifungal drugs market: drug class movement analysis
  • Fig. 19 U.S. antifungal drugs market: drug class outlook and key takeaways
  • Fig. 20 Azoles market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Echinocandins market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Polyenes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Allylamines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. antifungal drugs market: by indication, movement analysis
  • Fig. 26 U.S. antifungal drugs market: indication outlook and key takeaways
  • Fig. 27 Dermatophytosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Aspergillosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Candidiasis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. antifungal drugs market: by dosage form, movement analysis
  • Fig. 32 U.S. antifungal drugs market: dosage form outlook and key takeaways
  • Fig. 33 Oral drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Powders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. antifungal drugs market: by distribution channel, movement analysis
  • Fig. 38 U.S. antifungal drugs market: distribution channel outlook and key takeaways
  • Fig. 39 Hospital pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 OtherOthers market estimates and forecasts, 2018 - 2030 (USD Million)